

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		23558	100	0.4	277	1.2	6222	26.7	46	0.2
	Age at baseline	<18	5290	12	0.2	80	1.5	1663	31.7	16	0.3
		18-19	1964	8	0.4	33	1.7	570	29.3	1	0.1
		20-24	5470	28	0.5	65	1.2	1464	27.0	10	0.2
		25-29	5110	28	0.6	47	0.9	1337	26.4	8	0.2
		30-34	3523	15	0.4	30	0.9	809	23.3	8	0.2
		35+	2201	9	0.4	22	1.0	379	17.5	3	0.1
	Years since diagnosis	5-9	2383	3	0.1	33	1.4	779	33.1	4	0.2
		10-14	7680	29	0.4	93	1.2	2187	28.7	20	0.3
		15-19	7552	40	0.5	88	1.2	1905	25.5	17	0.2
		20+	5943	28	0.5	63	1.1	1351	23.0	5	0.1
	Age at diagnosis	<1	1778	1	0.1	31	1.8	234	13.3	7	0.4
		1-4	7584	31	0.4	114	1.5	2398	31.9	11	0.1
		5-9	5282	32	0.6	42	0.8	1531	29.2	8	0.2
		10-14	4993	24	0.5	61	1.2	1333	27.0	10	0.2
		15-20	3921	12	0.3	29	0.8	726	18.8	10	0.3
Males	All cases		12463	48	0.4	120	1.0	3499	28.4	23	0.2
	Age at baseline	<18	2841	7	0.2	35	1.2	926	32.9	6	0.2
		18-19	1014	3	0.3	15	1.5	319	31.7	1	0.1
		20-24	2840	12	0.4	25	0.9	774	27.5	3	0.1
		25-29	2800	16	0.6	20	0.7	785	28.3	5	0.2
		30-34	1856	8	0.4	14	0.8	477	26.0	6	0.3
		35+	1112	2	0.2	11	1.0	218	19.9	2	0.2
	Years since diagnosis	5-9	1326	3	0.2	13	1.0	461	35.3	1	0.1
		10-14	4084	11	0.3	45	1.1	1223	30.2	11	0.3
		15-19	3918	23	0.6	32	0.8	1037	26.8	7	0.2
		20+	3135	11	0.4	30	1.0	778	25.1	4	0.1
	Age at diagnosis	<1	901	1	0.1	13	1.5	107	12.0	2	0.2
		1-4	3934	15	0.4	53	1.4	1316	33.7	5	0.1
		5-9	2955	16	0.5	16	0.5	892	30.5	4	0.1
		10-14	2603	10	0.4	19	0.7	734	28.4	6	0.2
		15-20	2070	6	0.3	19	0.9	450	22.1	6	0.3
Females	All cases		11095	52	0.5	157	1.4	2723	24.8	23	0.2
	Age at baseline	<18	2449	5	0.2	45	1.8	737	30.2	10	0.4
		18-19	950	5	0.5	18	1.9	251	26.7	.	.
		20-24	2630	16	0.6	40	1.5	690	26.4	7	0.3
		25-29	2310	12	0.5	27	1.2	552	24.1	3	0.1
		30-34	1667	7	0.4	16	1.0	332	20.2	2	0.1
		35+	1089	7	0.7	11	1.0	161	15.0	1	0.1
	Years since diagnosis	5-9	1057	.	.	20	1.9	318	30.4	3	0.3
		10-14	3596	18	0.5	48	1.3	964	27.0	9	0.3
		15-19	3634	17	0.5	56	1.6	868	24.1	10	0.3
		20+	2808	17	0.6	33	1.2	573	20.6	1	0.0
	Age at diagnosis	<1	877	.	.	18	2.1	127	14.6	5	0.6
		1-4	3650	16	0.4	61	1.7	1082	29.9	6	0.2
		5-9	2327	16	0.7	26	1.1	639	27.6	4	0.2
		10-14	2390	14	0.6	42	1.8	599	25.3	4	0.2
		15-20	1851	6	0.3	10	0.5	276	15.1	4	0.2

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		23558	40	0.2	5326	22.9	8782	37.8	2299	9.9
	Age at baseline	<18	5290	12	0.2	1464	28.0	1923	36.8	586	11.2
		18-19	1964	5	0.3	569	29.3	782	40.4	216	11.1
		20-24	5470	12	0.2	1372	25.3	2091	38.6	529	9.8
		25-29	5110	7	0.1	1077	21.3	2016	40.0	517	10.2
		30-34	3523	3	0.1	572	16.5	1315	37.8	292	8.4
		35+	2201	1	0.0	272	12.6	655	30.3	159	7.3
	Years since diagnosis	5-9	2383	1	0.0	541	23.1	922	39.3	221	9.4
		10-14	7680	29	0.4	1888	24.8	3045	40.1	850	11.2
		15-19	7552	10	0.1	1729	23.2	2855	38.3	728	9.7
		20+	5943	.	.	1168	19.9	1960	33.4	500	8.5
	Age at diagnosis	<1	1778	6	0.3	116	6.6	188	10.6	110	6.2
		1-4	7584	12	0.2	2484	33.2	3140	41.9	870	11.6
		5-9	5282	9	0.2	1351	25.9	2128	40.8	516	9.9
		10-14	4993	9	0.2	932	18.9	2039	41.3	547	11.1
		15-20	3921	4	0.1	443	11.5	1287	33.4	256	6.6
Males	All cases		12463	24	0.2	2786	22.6	4828	39.2	1288	10.4
	Age at baseline	<18	2841	8	0.3	750	26.8	1026	36.7	322	11.4
		18-19	1014	4	0.4	286	28.4	429	42.7	127	12.6
		20-24	2840	7	0.2	687	24.4	1090	38.8	283	10.1
		25-29	2800	5	0.2	589	21.3	1160	42.0	305	11.0
		30-34	1856	.	.	303	16.5	738	40.3	156	8.5
		35+	1112	.	.	171	15.6	385	35.2	95	8.7
	Years since diagnosis	5-9	1326	1	0.1	285	21.9	520	40.0	130	9.9
		10-14	4084	19	0.5	994	24.6	1676	41.5	484	12.0
		15-19	3918	4	0.1	871	22.5	1532	39.6	380	9.8
		20+	3135	.	.	636	20.5	1100	35.5	294	9.5
	Age at diagnosis	<1	901	4	0.4	53	5.9	85	9.5	53	5.9
		1-4	3934	8	0.2	1249	32.1	1642	42.3	480	12.3
		5-9	2955	6	0.2	725	24.9	1211	41.6	314	10.7
		10-14	2603	4	0.2	481	18.7	1123	43.6	287	11.1
		15-20	2070	2	0.1	278	13.7	767	37.7	154	7.6
Females	All cases		11095	16	0.1	2540	23.2	3954	36.1	1011	9.2
	Age at baseline	<18	2449	4	0.2	714	29.4	897	37.0	264	10.8
		18-19	950	1	0.1	283	30.3	353	37.8	89	9.5
		20-24	2630	5	0.2	685	26.3	1001	38.5	246	9.4
		25-29	2310	2	0.1	488	21.3	856	37.5	212	9.2
		30-34	1667	3	0.2	269	16.4	577	35.1	136	8.3
		35+	1089	1	0.1	101	9.4	270	25.2	64	6.0
	Years since diagnosis	5-9	1057	.	.	256	24.6	402	38.5	91	8.7
		10-14	3596	10	0.3	894	25.1	1369	38.5	366	10.3
		15-19	3634	6	0.2	858	23.9	1323	36.9	348	9.7
		20+	2808	.	.	532	19.2	860	31.0	206	7.4
	Age at diagnosis	<1	877	2	0.2	63	7.2	103	11.8	57	6.5
		1-4	3650	4	0.1	1235	34.3	1498	41.6	390	10.8
		5-9	2327	3	0.1	626	27.1	917	39.8	202	8.7
		10-14	2390	5	0.2	451	19.1	916	38.8	260	11.0
		15-20	1851	2	0.1	165	9.1	520	28.6	102	5.6

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		7245	49	0.7	275	3.8	4754	66.4	2	0.0
	Age at baseline	<18	2096	8	0.4	80	3.8	1432	69.0	1	0.0
		18-19	769	4	0.5	32	4.2	469	61.5	.	.
		20-24	1788	20	1.1	65	3.7	1156	65.2	.	.
		25-29	1459	13	0.9	46	3.2	944	65.3	1	0.1
		30-34	761	4	0.5	30	4.0	500	67.5	.	.
		35+	372	.	.	22	6.0	253	69.3	.	.
	Years since diagnosis	5-9	904	.	.	33	3.7	617	69.2	1	0.1
		10-14	2445	15	0.6	92	3.8	1719	71.0	.	.
		15-19	2236	21	0.9	87	3.9	1453	65.8	.	.
		20+	1660	13	0.8	63	3.8	965	58.9	1	0.1
	Age at diagnosis	<1	232	.	.	30	13.0	203	89.4	1	0.4
		1-4	3421	26	0.8	114	3.4	2098	61.8	1	0.0
		5-9	1754	17	1.0	42	2.4	1083	62.5	.	.
		10-14	1203	4	0.3	60	5.0	901	75.7	.	.
		15-20	635	2	0.3	29	4.7	469	75.9	.	.
Males	All cases		3827	23	0.6	119	3.1	2549	67.5	1	0.0
	Age at baseline	<18	1136	4	0.4	35	3.1	777	69.4	.	.
		18-19	411	1	0.2	15	3.7	254	62.1	.	.
		20-24	891	8	0.9	25	2.8	578	65.3	.	.
		25-29	783	8	1.0	19	2.5	516	66.8	1	0.1
		30-34	397	2	0.5	14	3.6	278	72.2	.	.
		35+	209	.	.	11	5.3	146	71.2	.	.
	Years since diagnosis	5-9	510	.	.	13	2.6	348	69.2	.	.
		10-14	1301	5	0.4	44	3.4	915	71.0	.	.
		15-19	1136	12	1.1	32	2.9	752	67.4	.	.
		20+	880	6	0.7	30	3.4	534	61.4	1	0.1
	Age at diagnosis	<1	110	.	.	13	12.0	94	88.7	.	.
		1-4	1809	12	0.7	53	3.0	1124	62.7	1	0.1
		5-9	935	8	0.9	16	1.7	598	65.0	.	.
		10-14	588	2	0.3	18	3.1	448	76.8	.	.
		15-20	385	1	0.3	19	5.0	285	76.2	.	.
Females	All cases		3418	26	0.8	156	4.6	2205	65.1	1	0.0
	Age at baseline	<18	960	4	0.4	45	4.7	655	68.6	1	0.1
		18-19	358	3	0.8	17	4.8	215	60.9	.	.
		20-24	897	12	1.3	40	4.5	578	65.1	.	.
		25-29	676	5	0.7	27	4.0	428	63.6	.	.
		30-34	364	2	0.6	16	4.4	222	62.4	.	.
		35+	163	.	.	11	6.8	107	66.9	.	.
	Years since diagnosis	5-9	394	.	.	20	5.1	269	69.2	1	0.3
		10-14	1144	10	0.9	48	4.2	804	70.9	.	.
		15-19	1100	9	0.8	55	5.0	701	64.1	.	.
		20+	780	7	0.9	33	4.3	431	56.0	.	.
	Age at diagnosis	<1	122	.	.	17	13.9	109	90.1	1	0.8
		1-4	1612	14	0.9	61	3.8	974	60.9	.	.
		5-9	819	9	1.1	26	3.2	485	59.7	.	.
		10-14	615	2	0.3	42	6.9	453	74.6	.	.
		15-20	250	1	0.4	10	4.1	184	75.4	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		7245	35	0.5	4833	68.0	5777	81.3	1880	26.3
	Age at baseline	<18	2096	12	0.6	1417	69.1	1650	80.4	518	25.0
		18-19	769	5	0.7	541	71.7	623	82.7	179	23.5
		20-24	1788	9	0.5	1263	71.6	1477	83.8	442	24.9
		25-29	1459	7	0.5	939	65.3	1161	80.8	406	28.1
		30-34	761	1	0.1	455	61.7	585	79.3	212	28.6
		35+	372	1	0.3	218	59.7	281	77.0	123	33.5
	Years since diagnosis	5-9	904	1	0.1	506	57.4	638	72.3	193	21.6
		10-14	2445	28	1.2	1730	72.0	2040	85.1	689	28.6
		15-19	2236	6	0.3	1557	70.9	1825	83.1	593	26.8
		20+	1660	.	.	1040	63.8	1274	78.2	405	24.7
	Age at diagnosis	<1	232	6	2.6	111	48.7	164	71.9	99	43.0
		1-4	3421	10	0.3	2419	72.0	2767	82.4	774	22.9
		5-9	1754	9	0.5	1194	69.5	1400	81.6	398	23.0
		10-14	1203	6	0.5	763	64.1	963	81.1	415	34.8
		15-20	635	4	0.6	346	56.1	483	78.3	194	31.3
Males	All cases		3827	21	0.6	2471	65.8	2996	79.8	1023	27.1
	Age at baseline	<18	1136	8	0.7	718	64.9	843	76.2	279	25.0
		18-19	411	4	1.0	270	66.0	321	78.9	99	24.3
		20-24	891	4	0.5	620	70.3	731	82.9	232	26.3
		25-29	783	5	0.6	500	65.1	623	81.1	232	30.0
		30-34	397	.	.	228	59.4	314	81.6	108	28.1
		35+	209	.	.	135	65.5	164	79.6	73	35.4
	Years since diagnosis	5-9	510	1	0.2	258	51.9	341	68.6	108	21.5
		10-14	1301	18	1.4	890	69.7	1057	83.0	378	29.5
		15-19	1136	2	0.2	771	69.0	920	82.4	302	27.0
		20+	880	.	.	552	63.8	678	78.2	235	27.0
	Age at diagnosis	<1	110	4	3.7	52	48.6	78	72.9	46	42.6
		1-4	1809	6	0.3	1214	68.2	1401	78.7	422	23.6
		5-9	935	6	0.6	622	68.1	731	80.2	237	25.8
		10-14	588	3	0.5	368	63.4	487	84.0	201	34.6
		15-20	385	2	0.5	215	57.3	299	79.7	117	31.3
Females	All cases		3418	14	0.4	2362	70.4	2781	83.0	857	25.3
	Age at baseline	<18	960	4	0.4	699	74.0	807	85.4	239	25.1
		18-19	358	1	0.3	271	78.3	302	87.3	80	22.6
		20-24	897	5	0.6	643	72.9	746	84.8	210	23.6
		25-29	676	2	0.3	439	65.5	538	80.4	174	25.8
		30-34	364	1	0.3	227	64.1	271	76.8	104	29.1
		35+	163	1	0.6	83	52.2	117	73.6	50	31.1
	Years since diagnosis	5-9	394	.	.	248	64.6	297	77.1	85	21.9
		10-14	1144	10	0.9	840	74.5	983	87.5	311	27.5
		15-19	1100	4	0.4	786	72.8	905	83.8	291	26.6
		20+	780	.	.	488	63.8	596	78.1	170	22.0
	Age at diagnosis	<1	122	2	1.6	59	48.8	86	71.1	53	43.4
		1-4	1612	4	0.2	1205	76.3	1366	86.6	352	22.0
		5-9	819	3	0.4	572	71.1	669	83.3	161	19.8
		10-14	615	3	0.5	395	64.8	476	78.3	214	35.0
		15-20	250	2	0.8	131	54.1	184	76.0	77	31.4

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		6067	43	0.7	9	0.1	3763	62.6	1	0.0
	Age at baseline	<18	1812	8	0.4	5	0.3	1183	65.8	.	.
		18-19	666	4	0.6	1	0.2	382	57.9	.	.
		20-24	1524	16	1.1	1	0.1	927	61.3	.	.
		25-29	1207	13	1.1	1	0.1	732	61.1	1	0.1
		30-34	590	2	0.3	1	0.2	363	63.1	.	.
		35+	268	176	66.7	.	.
	Years since diagnosis	5-9	777	.	.	1	0.1	522	68.0	.	.
		10-14	2049	12	0.6	4	0.2	1379	67.9	.	.
		15-19	1847	18	1.0	2	0.1	1111	60.7	.	.
		20+	1394	13	0.9	2	0.1	751	54.5	1	0.1
	Age at diagnosis	<1	127	109	87.2	.	.
		1-4	3030	26	0.9	7	0.2	1754	58.3	1	0.0
		5-9	1537	15	1.0	1	0.1	900	59.2	.	.
		10-14	940	2	0.2	1	0.1	681	72.9	.	.
		15-20	433	319	76.0	.	.
Males	All cases		3231	21	0.7	2	0.1	2053	64.2	1	0.0
	Age at baseline	<18	982	4	0.4	.	.	645	66.4	.	.
		18-19	359	1	0.3	1	0.3	208	58.3	.	.
		20-24	759	7	0.9	.	.	463	61.4	.	.
		25-29	660	8	1.2	.	.	419	64.0	1	0.2
		30-34	313	1	0.3	1	0.3	210	69.1	.	.
		35+	158	108	69.2	.	.
	Years since diagnosis	5-9	440	293	67.5	.	.
		10-14	1099	5	0.5	1	0.1	744	68.3	.	.
		15-19	949	10	1.1	.	.	593	63.3	.	.
		20+	743	6	0.8	1	0.1	423	57.4	1	0.1
	Age at diagnosis	<1	63	55	88.7	.	.
		1-4	1591	12	0.8	1	0.1	933	59.0	1	0.1
		5-9	829	7	0.9	1	0.1	509	62.3	.	.
		10-14	476	2	0.4	.	.	354	74.5	.	.
		15-20	272	202	76.8	.	.
Females	All cases		2836	22	0.8	7	0.2	1710	60.9	.	.
	Age at baseline	<18	830	4	0.5	5	0.6	538	65.2	.	.
		18-19	307	3	1.0	.	.	174	57.4	.	.
		20-24	765	9	1.2	1	0.1	464	61.2	.	.
		25-29	547	5	0.9	1	0.2	313	57.5	.	.
		30-34	277	1	0.4	.	.	153	56.5	.	.
		35+	110	68	63.0	.	.
	Years since diagnosis	5-9	337	.	.	1	0.3	229	68.6	.	.
		10-14	950	7	0.7	3	0.3	635	67.5	.	.
		15-19	898	8	0.9	2	0.2	518	58.1	.	.
		20+	651	7	1.1	1	0.2	328	51.1	.	.
	Age at diagnosis	<1	64	54	85.7	.	.
		1-4	1439	14	1.0	6	0.4	821	57.5	.	.
		5-9	708	8	1.1	.	.	391	55.7	.	.
		10-14	464	.	.	1	0.2	327	71.2	.	.
		15-20	161	117	74.5	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		6067	3	0.0	4668	78.4	5223	87.8	1204	20.0
	Age at baseline	<18	1812	.	.	1381	77.9	1524	86.1	333	18.6
		18-19	666	1	0.2	528	80.9	577	88.6	120	18.2
		20-24	1524	1	0.1	1222	81.4	1343	89.5	282	18.6
		25-29	1207	1	0.1	901	75.7	1038	87.2	258	21.5
		30-34	590	.	.	433	75.7	503	88.1	127	22.2
		35+	268	.	.	203	77.5	238	90.8	84	31.7
	Years since diagnosis	5-9	777	1	0.1	492	65.1	577	76.2	139	18.1
		10-14	2049	1	0.0	1681	83.5	1853	92.2	451	22.3
		15-19	1847	1	0.1	1501	82.8	1638	90.4	348	19.0
		20+	1394	.	.	994	72.6	1155	84.4	266	19.2
	Age at diagnosis	<1	127	.	.	96	76.8	115	92.0	26	20.6
		1-4	3030	1	0.0	2358	79.3	2584	87.0	530	17.6
		5-9	1537	1	0.1	1162	77.3	1300	86.5	264	17.4
		10-14	940	.	.	733	78.5	841	90.1	266	28.4
		15-20	433	1	0.2	319	76.7	383	92.1	118	28.0
Males	All cases		3231	3	0.1	2394	75.5	2729	86.1	685	21.4
	Age at baseline	<18	982	.	.	704	73.6	781	81.8	181	18.7
		18-19	359	1	0.3	265	74.2	299	84.2	66	18.5
		20-24	759	1	0.1	597	79.6	664	88.4	151	20.0
		25-29	660	1	0.2	484	74.6	568	87.4	163	24.8
		30-34	313	.	.	219	72.3	272	89.8	68	22.4
		35+	158	.	.	125	80.1	145	92.9	56	35.7
	Years since diagnosis	5-9	440	1	0.2	252	58.9	303	70.8	81	18.6
		10-14	1099	1	0.1	867	80.4	969	90.1	256	23.6
		15-19	949	1	0.1	747	80.0	833	89.3	182	19.4
		20+	743	.	.	528	72.1	624	85.1	166	22.5
	Age at diagnosis	<1	63	.	.	46	74.2	57	91.9	13	21.0
		1-4	1591	1	0.1	1186	75.8	1309	83.7	282	17.9
		5-9	829	1	0.1	608	75.1	689	85.2	173	21.1
		10-14	476	.	.	356	75.3	434	91.6	144	30.4
		15-20	272	1	0.4	198	75.6	240	91.6	73	27.7
Females	All cases		2836	.	.	2274	81.8	2494	89.8	519	18.5
	Age at baseline	<18	830	.	.	677	83.0	743	91.1	152	18.5
		18-19	307	.	.	263	88.9	278	93.9	54	17.8
		20-24	765	.	.	625	83.2	679	90.5	131	17.3
		25-29	547	.	.	417	77.1	470	87.0	95	17.4
		30-34	277	.	.	214	79.6	231	86.2	59	21.6
		35+	110	.	.	78	73.6	93	87.7	28	25.9
	Years since diagnosis	5-9	337	.	.	240	73.2	274	83.3	58	17.4
		10-14	950	.	.	814	87.1	884	94.7	195	20.7
		15-19	898	.	.	754	85.8	805	91.6	166	18.6
		20+	651	.	.	466	73.2	531	83.6	100	15.5
	Age at diagnosis	<1	64	.	.	50	79.4	58	92.1	13	20.3
		1-4	1439	.	.	1172	83.3	1275	90.7	248	17.4
		5-9	708	.	.	554	79.8	611	88.0	91	13.0
		10-14	464	.	.	377	81.8	407	88.7	122	26.4
		15-20	161	.	.	121	78.6	143	92.9	45	28.7

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		871	5	0.6	248	28.9	814	95.1	1	0.1
	Age at baseline	<18	225	.	.	70	31.8	211	95.5	1	0.4
		18-19	82	.	.	29	35.8	74	91.4	.	.
		20-24	191	4	2.1	63	33.7	182	96.3	.	.
		25-29	186	.	.	41	22.2	179	97.3	.	.
		30-34	118	1	0.9	25	21.6	107	93.0	.	.
		35+	69	.	.	20	29.4	61	92.4	.	.
	Years since diagnosis	5-9	81	.	.	32	41.0	76	96.2	1	1.3
		10-14	307	2	0.7	83	27.4	289	95.1	.	.
		15-19	301	3	1.0	78	26.2	282	95.3	.	.
		20+	182	.	.	55	30.9	167	94.4	.	.
	Age at diagnosis	<1	90	.	.	27	30.3	84	94.4	1	1.1
		1-4	299	.	.	102	34.7	281	95.6	.	.
		5-9	163	2	1.2	38	23.8	153	95.0	.	.
		10-14	182	2	1.1	54	30.3	172	96.6	.	.
		15-20	137	1	0.7	27	19.9	124	92.5	.	.
Males	All cases		427	2	0.5	108	25.8	396	95.2	.	.
	Age at baseline	<18	122	.	.	32	27.1	112	94.9	.	.
		18-19	42	.	.	13	31.0	39	92.9	.	.
		20-24	92	1	1.1	25	27.8	88	96.7	.	.
		25-29	82	.	.	16	19.8	78	97.5	.	.
		30-34	56	1	1.8	12	21.8	51	94.4	.	.
		35+	33	.	.	10	31.3	28	90.3	.	.
	Years since diagnosis	5-9	47	.	.	13	28.9	44	95.7	.	.
		10-14	152	.	.	41	27.3	145	97.3	.	.
		15-19	141	2	1.4	28	20.1	128	93.4	.	.
		20+	87	.	.	26	31.0	79	94.0	.	.
	Age at diagnosis	<1	39	.	.	12	31.6	35	92.1	.	.
		1-4	165	.	.	48	29.6	154	95.7	.	.
		5-9	75	1	1.4	14	19.2	70	95.9	.	.
		10-14	74	.	.	17	23.6	69	95.8	.	.
		15-20	74	1	1.4	17	23.3	68	94.4	.	.
Females	All cases		444	3	0.7	140	31.9	418	95.0	1	0.2
	Age at baseline	<18	103	.	.	38	37.3	99	96.1	1	1.0
		18-19	40	.	.	16	41.0	35	89.7	.	.
		20-24	99	3	3.1	38	39.2	94	95.9	.	.
		25-29	104	.	.	25	24.0	101	97.1	.	.
		30-34	62	.	.	13	21.3	56	91.8	.	.
		35+	36	.	.	10	27.8	33	94.3	.	.
	Years since diagnosis	5-9	34	.	.	19	57.6	32	97.0	1	3.0
		10-14	155	2	1.3	42	27.5	144	92.9	.	.
		15-19	160	1	0.6	50	31.4	154	96.9	.	.
		20+	95	.	.	29	30.9	88	94.6	.	.
	Age at diagnosis	<1	51	.	.	15	29.4	49	96.1	1	2.0
		1-4	134	.	.	54	40.9	127	95.5	.	.
		5-9	88	1	1.1	24	27.6	83	94.3	.	.
		10-14	108	2	1.9	37	34.9	103	97.2	.	.
		15-20	63	.	.	10	15.9	56	90.3	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		871	31	3.6	91	10.6	390	45.3	589	69.3
	Age at baseline	<18	225	11	4.9	21	9.5	94	42.3	168	77.1
		18-19	82	4	4.9	6	7.4	37	45.7	51	63.0
		20-24	191	8	4.2	17	8.9	91	48.1	132	71.0
		25-29	186	6	3.2	27	14.6	88	47.6	133	72.3
		30-34	118	1	0.9	12	10.4	54	46.6	71	62.3
		35+	69	1	1.5	8	11.8	26	38.2	34	50.7
	Years since diagnosis	5-9	81	.	.	6	7.6	40	50.6	50	64.1
		10-14	307	26	8.5	27	8.9	139	45.9	216	71.8
		15-19	301	5	1.7	37	12.4	142	47.3	205	69.5
		20+	182	.	.	21	11.8	69	38.5	118	67.0
	Age at diagnosis	<1	90	5	5.6	13	14.6	39	43.8	67	75.3
		1-4	299	9	3.0	27	9.1	127	42.6	211	72.5
		5-9	163	8	4.9	17	10.6	73	45.6	113	71.5
		10-14	182	6	3.4	17	9.6	85	48.0	130	73.0
		15-20	137	3	2.2	17	12.4	66	48.2	68	50.7
Males	All cases		427	18	4.3	35	8.3	172	40.8	282	68.6
	Age at baseline	<18	122	8	6.6	7	5.9	45	37.5	89	76.1
		18-19	42	3	7.1	2	4.8	18	42.9	27	64.3
		20-24	92	3	3.3	8	8.7	41	44.6	63	71.6
		25-29	82	4	4.9	9	11.1	34	42.0	59	73.8
		30-34	56	.	.	5	9.3	25	45.5	31	58.5
		35+	33	.	.	4	12.5	9	28.1	13	41.9
	Years since diagnosis	5-9	47	.	.	3	6.5	25	54.3	24	53.3
		10-14	152	17	11.3	10	6.7	60	40.0	110	74.3
		15-19	141	1	0.7	15	10.7	63	44.7	94	69.1
		20+	87	.	.	7	8.3	24	28.2	54	65.9
	Age at diagnosis	<1	39	4	10.5	6	15.8	16	42.1	31	81.6
		1-4	165	5	3.0	8	4.9	61	37.0	117	73.1
		5-9	75	5	6.8	7	9.6	28	37.8	50	71.4
		10-14	74	3	4.2	4	5.6	32	45.1	48	66.7
		15-20	74	1	1.4	10	13.5	35	47.3	36	50.7
Females	All cases		444	13	2.9	56	12.7	218	49.7	307	69.9
	Age at baseline	<18	103	3	2.9	14	13.7	49	48.0	79	78.2
		18-19	40	1	2.6	4	10.3	19	48.7	24	61.5
		20-24	99	5	5.1	9	9.2	50	51.5	69	70.4
		25-29	104	2	1.9	18	17.3	54	51.9	74	71.2
		30-34	62	1	1.6	7	11.5	29	47.5	40	65.6
		35+	36	1	2.8	4	11.1	17	47.2	21	58.3
	Years since diagnosis	5-9	34	.	.	3	9.1	15	45.5	26	78.8
		10-14	155	9	5.8	17	11.0	79	51.6	106	69.3
		15-19	160	4	2.5	22	13.8	79	49.7	111	69.8
		20+	95	.	.	14	14.9	45	47.9	64	68.1
	Age at diagnosis	<1	51	1	2.0	7	13.7	23	45.1	36	70.6
		1-4	134	4	3.0	19	14.3	66	49.6	94	71.8
		5-9	88	3	3.4	10	11.5	45	52.3	63	71.6
		10-14	108	3	2.8	13	12.3	53	50.0	82	77.4
		15-20	63	2	3.2	7	11.1	31	49.2	32	50.8

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		4184	2	0.0	1	0.0	157	3.8	11	0.3
	Age at baseline	<18	891	1	0.1	.	.	53	6.0	3	0.3
		18-19	349	.	.	1	0.3	10	2.9	1	0.3
		20-24	1093	1	0.1	.	.	31	2.9	3	0.3
		25-29	1021	36	3.6	3	0.3
		30-34	581	19	3.3	1	0.2
		35+	249	8	3.3	.	.
	Years since diagnosis	5-9	428	46	11.0	.	.
		10-14	1424	2	0.1	.	.	37	2.6	7	0.5
		15-19	1325	.	.	1	0.1	13	1.0	4	0.3
		20+	1007	61	6.1	.	.
	Age at diagnosis	<1	205	.	.	1	0.5	11	5.4	2	1.0
		1-4	1223	53	4.4	2	0.2
		5-9	1326	2	0.2	.	.	54	4.1	2	0.2
		10-14	996	30	3.0	4	0.4
		15-20	434	9	2.1	1	0.2
Males	All cases		2276	1	0.0	.	.	92	4.1	8	0.4
	Age at baseline	<18	494	34	7.0	2	0.4
		18-19	176	4	2.4	1	0.6
		20-24	584	1	0.2	.	.	18	3.1	2	0.3
		25-29	579	24	4.2	3	0.5
		30-34	309	9	3.0	.	.
		35+	134	3	2.3	.	.
	Years since diagnosis	5-9	242	28	11.9	.	.
		10-14	766	1	0.1	.	.	25	3.3	5	0.7
		15-19	720	7	1.0	3	0.4
		20+	548	32	5.9	.	.
	Age at diagnosis	<1	121	7	5.8	2	1.7
		1-4	647	30	4.7	1	0.2
		5-9	738	1	0.1	.	.	32	4.4	1	0.1
		10-14	526	16	3.1	4	0.8
		15-20	244	7	3.0	.	.
Females	All cases		1908	1	0.1	1	0.1	65	3.4	3	0.2
	Age at baseline	<18	397	1	0.3	.	.	19	4.8	1	0.3
		18-19	173	.	.	1	0.6	6	3.6	.	.
		20-24	509	13	2.6	1	0.2
		25-29	442	12	2.8	.	.
		30-34	272	10	3.7	1	0.4
		35+	115	5	4.3	.	.
	Years since diagnosis	5-9	186	18	9.8	.	.
		10-14	658	1	0.2	.	.	12	1.8	2	0.3
		15-19	605	.	.	1	0.2	6	1.0	1	0.2
		20+	459	29	6.3	.	.
	Age at diagnosis	<1	84	.	.	1	1.2	4	4.8	.	.
		1-4	576	23	4.0	1	0.2
		5-9	588	1	0.2	.	.	22	3.8	1	0.2
		10-14	470	14	3.0	.	.
		15-20	190	2	1.1	1	0.5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
		All cases		N	%	N	%	N	%	N	%
Both sexes	All cases	4184		.	.	7	0.2	58	1.4	67	1.6
	Age at baseline	<18	891	.	.	1	0.1	18	2.0	25	2.8
		18-19	349	6	1.8	8	2.3
		20-24	1093	.	.	2	0.2	19	1.8	15	1.4
		25-29	1021	.	.	3	0.3	8	0.8	15	1.5
		30-34	581	7	1.2	2	0.3
		35+	249	.	.	1	0.4	.	.	2	0.8
	Years since diagnosis	5-9	428	.	.	1	0.2	12	2.9	6	1.4
		10-14	1424	.	.	1	0.1	17	1.2	38	2.7
		15-19	1325	.	.	2	0.2	16	1.2	17	1.3
		20+	1007	.	.	3	0.3	13	1.3	6	0.6
	Age at diagnosis	<1	205	9	4.4	8	3.9
		1-4	1223	.	.	3	0.2	17	1.4	26	2.2
		5-9	1326	.	.	4	0.3	18	1.4	15	1.1
		10-14	996	11	1.1	12	1.2
		15-20	434	3	0.7	6	1.4
Males	All cases	2276		.	.	6	0.3	37	1.7	39	1.7
	Age at baseline	<18	494	.	.	1	0.2	10	2.1	17	3.5
		18-19	176	3	1.7	4	2.3
		20-24	584	.	.	2	0.3	13	2.3	8	1.4
		25-29	579	.	.	2	0.3	7	1.2	7	1.2
		30-34	309	4	1.3	1	0.3
		35+	134	.	.	1	0.8	.	.	2	1.6
	Years since diagnosis	5-9	242	.	.	1	0.4	8	3.4	4	1.7
		10-14	766	.	.	1	0.1	10	1.3	24	3.2
		15-19	720	.	.	2	0.3	10	1.4	8	1.1
		20+	548	.	.	2	0.4	9	1.7	3	0.6
	Age at diagnosis	<1	121	4	3.3	7	5.8
		1-4	647	.	.	2	0.3	11	1.7	13	2.0
		5-9	738	.	.	4	0.5	13	1.8	9	1.2
		10-14	526	7	1.3	5	1.0
		15-20	244	2	0.9	5	2.1
Females	All cases	1908		.	.	1	0.1	21	1.1	28	1.5
	Age at baseline	<18	397	8	2.0	8	2.0
		18-19	173	3	1.8	4	2.4
		20-24	509	6	1.2	7	1.4
		25-29	442	.	.	1	0.2	1	0.2	8	1.8
		30-34	272	3	1.1	1	0.4
		35+	115
	Years since diagnosis	5-9	186	4	2.2	2	1.1
		10-14	658	7	1.1	14	2.1
		15-19	605	6	1.0	9	1.5
		20+	459	.	.	1	0.2	4	0.9	3	0.7
	Age at diagnosis	<1	84	5	6.0	1	1.2
		1-4	576	.	.	1	0.2	6	1.1	13	2.3
		5-9	588	5	0.9	6	1.0
		10-14	470	4	0.9	7	1.5
		15-20	190	1	0.5	1	0.5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		2509	52	2.1	10	0.4
	Age at baseline	<18	493	17	3.5	2	0.4
		18-19	202	1	0.5	1	0.5
		20-24	662	11	1.7	3	0.5
		25-29	629	14	2.3	3	0.5
		30-34	357	8	2.2	1	0.3
		35+	166	1	0.6	.	.
	Years since diagnosis	5-9	219	12	5.5	.	.
		10-14	838	16	1.9	6	0.7
		15-19	778	2	0.3	4	0.5
		20+	674	22	3.3	.	.
	Age at diagnosis	<1	144	7	4.9	2	1.4
		1-4	741	11	1.5	1	0.1
		5-9	750	21	2.8	2	0.3
		10-14	599	10	1.7	4	0.7
		15-20	275	3	1.1	1	0.4
Males	All cases		1302	35	2.7	8	0.6
	Age at baseline	<18	258	16	6.3	2	0.8
		18-19	102	1	1.0	1	1.0
		20-24	325	7	2.2	2	0.6
		25-29	351	7	2.0	3	0.9
		30-34	178	4	2.3	.	.
		35+	88
	Years since diagnosis	5-9	117	10	8.5	.	.
		10-14	437	14	3.2	5	1.2
		15-19	391	1	0.3	3	0.8
		20+	357	10	2.8	.	.
	Age at diagnosis	<1	81	6	7.4	2	2.5
		1-4	373	8	2.2	1	0.3
		5-9	394	14	3.6	1	0.3
		10-14	302	5	1.7	4	1.3
		15-20	152	2	1.3	.	.
Females	All cases		1207	17	1.4	2	0.2
	Age at baseline	<18	235	1	0.4	.	.
		18-19	100
		20-24	337	4	1.2	1	0.3
		25-29	278	7	2.6	.	.
		30-34	179	4	2.2	1	0.6
		35+	78	1	1.3	.	.
	Years since diagnosis	5-9	102	2	2.0	.	.
		10-14	401	2	0.5	1	0.3
		15-19	387	1	0.3	1	0.3
		20+	317	12	3.8	.	.
	Age at diagnosis	<1	63	1	1.6	.	.
		1-4	368	3	0.8	.	.
		5-9	356	7	2.0	1	0.3
		10-14	297	5	1.7	.	.
		15-20	123	1	0.8	1	0.8

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		2509	.	.	1	0.0	17	0.7	56	2.3
	Age at baseline	<18	493	4	0.8	20	4.1
		18-19	202	3	1.5	6	3.0
		20-24	662	.	.	1	0.2	6	0.9	13	2.0
		25-29	629	1	0.2	14	2.3
		30-34	357	3	0.8	1	0.3
		35+	166	2	1.2
	Years since diagnosis	5-9	219	5	2.3
		10-14	838	.	.	1	0.1	5	0.6	33	4.0
		15-19	778	7	0.9	13	1.7
		20+	674	5	0.7	5	0.7
	Age at diagnosis	<1	144	5	3.5	6	4.2
		1-4	741	4	0.5	20	2.7
		5-9	750	.	.	1	0.1	5	0.7	14	1.9
		10-14	599	3	0.5	10	1.7
		15-20	275	6	2.2
Males	All cases		1302	.	.	1	0.1	10	0.8	33	2.6
	Age at baseline	<18	258	3	1.2	14	5.5
		18-19	102	3	3.0
		20-24	325	.	.	1	0.3	5	1.5	6	1.9
		25-29	351	1	0.3	7	2.0
		30-34	178	1	0.6	1	0.6
		35+	88	2	2.3
	Years since diagnosis	5-9	117	3	2.6
		10-14	437	.	.	1	0.2	5	1.2	21	4.9
		15-19	391	2	0.5	7	1.8
		20+	357	3	0.8	2	0.6
	Age at diagnosis	<1	81	2	2.5	5	6.2
		1-4	373	2	0.5	10	2.7
		5-9	394	.	.	1	0.3	5	1.3	9	2.3
		10-14	302	1	0.3	4	1.3
		15-20	152	5	3.4
Females	All cases		1207	7	0.6	23	1.9
	Age at baseline	<18	235	1	0.4	6	2.6
		18-19	100	3	3.1	3	3.1
		20-24	337	1	0.3	7	2.1
		25-29	278	7	2.6
		30-34	179	2	1.1	.	.
		35+	78
	Years since diagnosis	5-9	102	2	2.0
		10-14	401	12	3.0
		15-19	387	5	1.3	6	1.6
		20+	317	2	0.6	3	1.0
	Age at diagnosis	<1	63	3	4.8	1	1.6
		1-4	368	2	0.6	10	2.8
		5-9	356	5	1.4
		10-14	297	2	0.7	6	2.0
		15-20	123	1	0.8

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		979	2	0.2	.	.	80	8.3	.	.
	Age at baseline	<18	233	1	0.4	.	.	26	11.3	.	.
		18-19	77	6	8.2	.	.
		20-24	273	1	0.4	.	.	13	4.8	.	.
		25-29	236	17	7.3	.	.
		30-34	126	11	8.8	.	.
		35+	34	7	21.9	.	.
	Years since diagnosis	5-9	119	22	19.3	.	.
		10-14	333	2	0.6	.	.	17	5.2	.	.
		15-19	323	9	2.8	.	.
		20+	204	32	15.9	.	.
	Age at diagnosis	<1	23	1	4.5	.	.
		1-4	279	30	10.9	.	.
		5-9	402	2	0.5	.	.	28	7.0	.	.
		10-14	217	17	8.0	.	.
		15-20	58	4	7.3	.	.
Males	All cases		599	1	0.2	.	.	47	8.0	.	.
	Age at baseline	<18	141	15	10.9	.	.
		18-19	43	1	2.5	.	.
		20-24	177	1	0.6	.	.	8	4.6	.	.
		25-29	145	15	10.4	.	.
		30-34	71	5	7.1	.	.
		35+	22	3	15.0	.	.
	Years since diagnosis	5-9	72	12	17.9	.	.
		10-14	196	1	0.5	.	.	10	5.2	.	.
		15-19	207	5	2.4	.	.
		20+	124	20	16.5	.	.
	Age at diagnosis	<1	16	1	6.7	.	.
		1-4	168	17	10.3	.	.
		5-9	257	1	0.4	.	.	17	6.7	.	.
		10-14	123	9	7.5	.	.
		15-20	35	3	9.4	.	.
Females	All cases		380	1	0.3	.	.	33	8.8	.	.
	Age at baseline	<18	92	1	1.1	.	.	11	12.0	.	.
		18-19	34	5	15.2	.	.
		20-24	96	5	5.3	.	.
		25-29	91	2	2.2	.	.
		30-34	55	6	10.9	.	.
		35+	12	4	33.3	.	.
	Years since diagnosis	5-9	47	10	21.3	.	.
		10-14	137	1	0.7	.	.	7	5.1	.	.
		15-19	116	4	3.5	.	.
		20+	80	12	15.0	.	.
	Age at diagnosis	<1	7
		1-4	111	13	11.8	.	.
		5-9	145	1	0.7	.	.	11	7.6	.	.
		10-14	94	8	8.6	.	.
		15-20	23	1	4.3	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		979	.	.	5	0.5	31	3.2	5	0.5
	Age at baseline	<18	233	.	.	1	0.4	9	3.9	3	1.3
		18-19	77	2	2.7	.	.
		20-24	273	.	.	1	0.4	11	4.1	1	0.4
		25-29	236	.	.	2	0.9	6	2.6	.	.
		30-34	126	3	2.4	1	0.8
		35+	34	.	.	1	3.1
	Years since diagnosis	5-9	119	.	.	1	0.9	8	7.0	1	0.9
		10-14	333	8	2.4	2	0.6
		15-19	323	.	.	2	0.6	8	2.5	1	0.3
		20+	204	.	.	2	1.0	7	3.5	1	0.5
	Age at diagnosis	<1	23	3	13.6	1	4.5
		1-4	279	.	.	2	0.7	9	3.3	3	1.1
		5-9	402	.	.	3	0.8	11	2.8	.	.
		10-14	217	6	2.8	1	0.5
		15-20	58	2	3.6	.	.
Males	All cases		599	.	.	5	0.9	21	3.6	3	0.5
	Age at baseline	<18	141	.	.	1	0.7	5	3.6	2	1.4
		18-19	43	2	4.9	.	.
		20-24	177	.	.	1	0.6	7	4.0	1	0.6
		25-29	145	.	.	2	1.4	5	3.5	.	.
		30-34	71	2	2.9	.	.
		35+	22	.	.	1	5.0
	Years since diagnosis	5-9	72	.	.	1	1.5	5	7.4	1	1.5
		10-14	196	4	2.1	1	0.5
		15-19	207	.	.	2	1.0	7	3.4	.	.
		20+	124	.	.	2	1.7	5	4.1	1	0.8
	Age at diagnosis	<1	16	2	13.3	1	6.7
		1-4	168	.	.	2	1.2	7	4.2	2	1.2
		5-9	257	.	.	3	1.2	6	2.4	.	.
		10-14	123	5	4.1	.	.
		15-20	35	1	3.1	.	.
Females	All cases		380	10	2.7	2	0.5
	Age at baseline	<18	92	4	4.3	1	1.1
		18-19	34
		20-24	96	4	4.2	.	.
		25-29	91	1	1.1	.	.
		30-34	55	1	1.8	1	1.8
		35+	12
	Years since diagnosis	5-9	47	3	6.4	.	.
		10-14	137	4	2.9	1	0.7
		15-19	116	1	0.9	1	0.9
		20+	80	2	2.5	.	.
	Age at diagnosis	<1	7	1	14.3	.	.
		1-4	111	2	1.8	1	0.9
		5-9	145	5	3.5	.	.
		10-14	94	1	1.1	1	1.1
		15-20	23	1	4.3	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		2827	29	1.0	.	.	93	3.3	2	0.1
	Age at baseline	<18	55	2	3.6	.	.
		18-19	55	3	5.5	.	.
		20-24	328	3	0.9	.	.	9	2.8	1	0.3
		25-29	733	9	1.2	.	.	25	3.4	.	.
		30-34	862	9	1.1	.	.	33	3.9	1	0.1
		35+	794	8	1.0	.	.	21	2.7	.	.
	Years since diagnosis	5-9	221	1	0.5	.	.	11	5.1	1	0.5
		10-14	867	5	0.6	.	.	31	3.6	.	.
		15-19	930	11	1.2	.	.	25	2.7	.	.
		20+	809	12	1.5	.	.	26	3.3	1	0.1
	Age at diagnosis	1-4	71
		5-9	353	5	1.4	.	.	6	1.7	1	0.3
		10-14	1026	17	1.7	.	.	46	4.5	.	.
		15-20	1377	7	0.5	.	.	41	3.0	1	0.1
Males	All cases		1458	13	0.9	.	.	54	3.8	1	0.1
	Age at baseline	<18	42	1	2.4	.	.
		18-19	44	2	4.5	.	.
		20-24	207	2	1.0	.	.	6	3.0	.	.
		25-29	401	4	1.0	.	.	13	3.3	.	.
		30-34	429	5	1.2	.	.	23	5.4	1	0.2
		35+	335	2	0.6	.	.	9	2.7	.	.
	Years since diagnosis	5-9	126	1	0.8	.	.	8	6.5	.	.
		10-14	441	1	0.2	.	.	17	3.9	.	.
		15-19	492	8	1.6	.	.	16	3.3	.	.
		20+	399	3	0.8	.	.	13	3.3	1	0.3
	Age at diagnosis	1-4	52
		5-9	259	4	1.6	.	.	2	0.8	1	0.4
		10-14	522	5	1.0	.	.	25	4.8	.	.
		15-20	625	4	0.6	.	.	27	4.4	.	.
Females	All cases		1369	16	1.2	.	.	39	2.9	1	0.1
	Age at baseline	<18	13	1	7.7	.	.
		18-19	11	1	9.1	.	.
		20-24	121	1	0.8	.	.	3	2.5	1	0.8
		25-29	332	5	1.5	.	.	12	3.6	.	.
		30-34	433	4	0.9	.	.	10	2.4	.	.
		35+	459	6	1.3	.	.	12	2.7	.	.
	Years since diagnosis	5-9	95	3	3.2	1	1.1
		10-14	426	4	1.0	.	.	14	3.3	.	.
		15-19	438	3	0.7	.	.	9	2.1	.	.
		20+	410	9	2.2	.	.	13	3.2	.	.
	Age at diagnosis	1-4	19
		5-9	94	1	1.1	.	.	4	4.3	.	.
		10-14	504	12	2.4	.	.	21	4.2	.	.
		15-20	752	3	0.4	.	.	14	1.9	1	0.1

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		2827	.	.	4	0.1	177	6.3	1	0.0
	Age at baseline	<18	55	7	12.7	.	.
		18-19	55	4	7.3	.	.
		20-24	328	20	6.2	.	.
		25-29	733	.	.	1	0.1	87	12.0	.	.
		30-34	862	.	.	2	0.2	49	5.8	.	.
		35+	794	.	.	1	0.1	10	1.3	1	0.1
	Years since diagnosis	5-9	221	18	8.3	.	.
		10-14	867	.	.	2	0.2	94	11.0	.	.
		15-19	930	59	6.4	.	.
		20+	809	.	.	2	0.3	6	0.8	1	0.1
	Age at diagnosis	1-4	71	4	5.7	.	.
		5-9	353	25	7.1	.	.
		10-14	1026	.	.	1	0.1	59	5.8	.	.
		15-20	1377	.	.	3	0.2	89	6.6	1	0.1
Males	All cases		1458	.	.	3	0.2	97	6.7	1	0.1
	Age at baseline	<18	42	6	14.3	.	.
		18-19	44	3	6.8	.	.
		20-24	207	14	6.9	.	.
		25-29	401	.	.	1	0.3	45	11.4	.	.
		30-34	429	.	.	1	0.2	26	6.1	.	.
		35+	335	.	.	1	0.3	3	0.9	1	0.3
	Years since diagnosis	5-9	126	11	8.9	.	.
		10-14	441	.	.	1	0.2	48	11.0	.	.
		15-19	492	34	7.0	.	.
		20+	399	.	.	2	0.5	4	1.0	1	0.3
	Age at diagnosis	1-4	52	4	7.8	.	.
		5-9	259	19	7.4	.	.
		10-14	522	.	.	1	0.2	33	6.4	.	.
		15-20	625	.	.	2	0.3	41	6.7	1	0.2
Females	All cases		1369	.	.	1	0.1	80	5.9	.	.
	Age at baseline	<18	13	1	7.7	.	.
		18-19	11	1	9.1	.	.
		20-24	121	6	5.0	.	.
		25-29	332	42	12.8	.	.
		30-34	433	.	.	1	0.2	23	5.4	.	.
		35+	459	7	1.5	.	.
	Years since diagnosis	5-9	95	7	7.4	.	.
		10-14	426	.	.	1	0.2	46	11.0	.	.
		15-19	438	25	5.8	.	.
		20+	410	2	0.5	.	.
	Age at diagnosis	1-4	19
		5-9	94	6	6.4	.	.
		10-14	504	26	5.2	.	.
		15-20	752	.	.	1	0.1	48	6.5	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases	1915	9	0.5	1	0.1	1106	58.4	1	0.1	
	Age at baseline	<18	200	2	1.0	.	.	134	67.7	1	0.5
		18-19	119	1	0.8	.	.	79	66.9	.	.
		20-24	405	1	0.2	.	.	241	60.0	.	.
		25-29	526	4	0.8	1	0.2	311	60.0	.	.
		30-34	438	247	56.7	.	.
		35+	227	1	0.4	.	.	94	42.2	.	.
	Years since diagnosis	5-9	132	2	1.5	.	.	81	61.8	.	.
		10-14	609	3	0.5	1	0.2	359	59.3	1	0.2
		15-19	657	3	0.5	.	.	395	60.7	.	.
		20+	517	1	0.2	.	.	271	53.3	.	.
	Age at diagnosis	<1	12	6	50.0	.	.
		1-4	315	2	0.6	.	.	207	67.2	1	0.3
		5-9	579	3	0.5	.	.	354	61.7	.	.
		10-14	602	3	0.5	1	0.2	341	56.8	.	.
		15-20	407	1	0.2	.	.	198	49.4	.	.
Males	All cases	1290	6	0.5	1	0.1	744	58.3	.	.	
	Age at baseline	<18	138	2	1.5	.	.	93	68.4	.	.
		18-19	87	1	1.2	.	.	54	62.8	.	.
		20-24	264	160	60.8	.	.
		25-29	367	3	0.8	1	0.3	219	60.5	.	.
		30-34	286	160	56.3	.	.
		35+	148	58	39.7	.	.
	Years since diagnosis	5-9	99	2	2.0	.	.	61	62.2	.	.
		10-14	413	2	0.5	1	0.2	248	60.5	.	.
		15-19	426	2	0.5	.	.	254	60.0	.	.
		20+	352	181	52.3	.	.
	Age at diagnosis	<1	3
		1-4	211	1	0.5	.	.	140	68.0	.	.
		5-9	404	2	0.5	.	.	244	61.0	.	.
		10-14	409	3	0.7	1	0.2	235	57.5	.	.
		15-20	263	125	48.3	.	.
Females	All cases	625	3	0.5	.	.	362	58.6	1	0.2	
	Age at baseline	<18	62	41	66.1	1	1.6
		18-19	32	25	78.1	.	.
		20-24	141	1	0.7	.	.	81	58.3	.	.
		25-29	159	1	0.6	.	.	92	59.0	.	.
		30-34	152	87	57.2	.	.
		35+	79	1	1.3	.	.	36	46.8	.	.
	Years since diagnosis	5-9	33	20	60.6	.	.
		10-14	196	1	0.5	.	.	111	56.9	1	0.5
		15-19	231	1	0.4	.	.	141	61.8	.	.
		20+	165	1	0.6	.	.	90	55.6	.	.
	Age at diagnosis	<1	9	6	66.7	.	.
		1-4	104	1	1.0	.	.	67	65.7	1	1.0
		5-9	175	1	0.6	.	.	110	63.2	.	.
		10-14	193	106	55.5	.	.
		15-20	144	1	0.7	.	.	73	51.4	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases	1915	2	0.1	476	25.1	1645	86.9	349	18.4	
	Age at baseline	<18	200	.	.	44	22.1	180	91.4	42	21.1
		18-19	119	.	.	28	23.7	111	94.1	29	24.6
		20-24	405	1	0.2	105	26.1	364	90.3	72	17.9
		25-29	526	.	.	132	25.4	460	89.1	95	18.3
		30-34	438	1	0.2	115	26.4	372	85.5	78	17.9
		35+	227	.	.	52	23.3	158	70.9	33	14.8
	Years since diagnosis	5-9	132	.	.	32	24.4	112	85.5	22	16.7
		10-14	609	.	.	153	25.2	532	88.2	122	20.2
		15-19	657	2	0.3	168	25.8	586	90.2	117	18.0
		20+	517	.	.	123	24.1	415	81.7	88	17.3
	Age at diagnosis	<1	12	.	.	5	41.7	9	75.0	3	25.0
		1-4	315	1	0.3	59	19.0	280	91.2	70	22.5
		5-9	579	.	.	152	26.4	514	89.5	101	17.6
		10-14	602	1	0.2	166	27.7	544	90.8	120	20.0
		15-20	407	.	.	94	23.4	298	74.5	55	13.7
Males	All cases	1290	1	0.1	303	23.7	1112	87.2	224	17.5	
	Age at baseline	<18	138	.	.	29	21.2	125	92.6	26	19.0
		18-19	87	.	.	16	18.6	82	95.3	24	27.9
		20-24	264	1	0.4	65	24.7	240	91.3	43	16.3
		25-29	367	.	.	85	23.5	325	90.0	65	17.9
		30-34	286	.	.	74	26.1	240	84.5	47	16.5
		35+	148	.	.	34	23.3	100	68.5	19	13.0
	Years since diagnosis	5-9	99	.	.	25	25.5	86	87.8	18	18.2
		10-14	413	.	.	100	24.3	370	90.5	82	20.0
		15-19	426	1	0.2	98	23.2	382	90.3	69	16.3
		20+	352	.	.	80	23.1	274	79.4	55	15.9
	Age at diagnosis	<1	3	.	.	1	33.3	1	33.3	.	.
		1-4	211	1	0.5	31	15.0	185	90.7	45	21.6
		5-9	404	.	.	99	24.7	361	90.3	67	16.7
		10-14	409	.	.	111	27.2	376	91.9	81	19.8
		15-20	263	.	.	61	23.6	189	73.0	31	11.9
Females	All cases	625	1	0.2	173	27.9	533	86.4	125	20.3	
	Age at baseline	<18	62	.	.	15	24.2	55	88.7	16	25.8
		18-19	32	.	.	12	37.5	29	90.6	5	15.6
		20-24	141	.	.	40	28.6	124	88.6	29	20.9
		25-29	159	.	.	47	29.9	135	87.1	30	19.2
		30-34	152	1	0.7	41	27.0	132	87.4	31	20.5
		35+	79	.	.	18	23.4	58	75.3	14	18.2
	Years since diagnosis	5-9	33	.	.	7	21.2	26	78.8	4	12.1
		10-14	196	.	.	53	27.2	162	83.5	40	20.6
		15-19	231	1	0.4	70	30.7	204	89.9	48	21.1
		20+	165	.	.	43	26.2	141	86.5	33	20.2
	Age at diagnosis	<1	9	.	.	4	44.4	8	88.9	3	33.3
		1-4	104	.	.	28	27.2	95	92.2	25	24.3
		5-9	175	.	.	53	30.3	153	87.9	34	19.5
		10-14	193	1	0.5	55	28.8	168	88.4	39	20.5
		15-20	144	.	.	33	23.2	109	77.3	24	17.0

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases	2070	3	0.1	.	.	.	4	0.2	5	0.2
	Age at baseline	<18	761	1	0.1	2	0.3
		18-19	275	1	0.4
		20-24	611	1	0.2	3	0.5
		25-29	342	1	0.3	.	.	3	0.9	.	.
		30-34	66
		35+	15
	Years since diagnosis	5-9	167	1	0.6
		10-14	675	2	0.3	2	0.3
		15-19	679	1	0.1	.	.	1	0.1	2	0.3
		20+	549	3	0.5	.	.
	Age at diagnosis	<1	301
		1-4	1261	1	0.1	.	.	2	0.2	2	0.2
		5-9	434	2	0.5	.	.	2	0.5	2	0.5
		10-14	54
		15-20	20	1	5.0
Males	All cases	917	1	0.1	.	.	.	3	0.3	3	0.3
	Age at baseline	<18	369	1	0.3	2	0.5
		18-19	111
		20-24	252	1	0.4
		25-29	152	3	2.0	.	.
		30-34	27
		35+	6
	Years since diagnosis	5-9	74
		10-14	307	1	0.3	2	0.7
		15-19	289	1	0.3
		20+	247	3	1.2	.	.
	Age at diagnosis	<1	149
		1-4	564	1	0.2	.	.	2	0.4	1	0.2
		5-9	177	1	0.6	2	1.1
		10-14	19
		15-20	8
Females	All cases	1153	2	0.2	.	.	.	1	0.1	2	0.2
	Age at baseline	<18	392
		18-19	164	1	0.6
		20-24	359	1	0.3	2	0.6
		25-29	190	1	0.5
		30-34	39
		35+	9
	Years since diagnosis	5-9	93	1	1.1
		10-14	368	1	0.3
		15-19	390	1	0.3	.	.	1	0.3	1	0.3
		20+	302
	Age at diagnosis	<1	152
		1-4	697	1	0.1
		5-9	257	2	0.8	.	.	1	0.4	.	.
		10-14	35
		15-20	12	1	8.3

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases	2070		.	.	1	0.0	1	0.0	1	0.0
	Age at baseline	<18	761	1	0.1
		18-19	275
		20-24	611	.	.	1	0.2	1	0.2	.	.
		25-29	342
		30-34	66
		35+	15
	Years since diagnosis	5-9	167
		10-14	675	1	0.1
		15-19	679	.	.	1	0.1	1	0.1	.	.
		20+	549
	Age at diagnosis	<1	301
		1-4	1261	.	.	1	0.1
		5-9	434	1	0.2	1	0.2
		10-14	54
		15-20	20
Males	All cases	917	
	Age at baseline	<18	369
		18-19	111
		20-24	252
		25-29	152
		30-34	27
		35+	6
	Years since diagnosis	5-9	74
		10-14	307
		15-19	289
		20+	247
	Age at diagnosis	<1	149
		1-4	564
		5-9	177
		10-14	19
		15-20	8
Females	All cases	1153		.	.	1	0.1	1	0.1	1	0.1
	Age at baseline	<18	392	1	0.3
		18-19	164
		20-24	359	.	.	1	0.3	1	0.3	.	.
		25-29	190
		30-34	39
		35+	9
	Years since diagnosis	5-9	93
		10-14	368	1	0.3
		15-19	390	.	.	1	0.3	1	0.3	.	.
		20+	302
	Age at diagnosis	<1	152
		1-4	697	.	.	1	0.1
		5-9	257	1	0.4	1	0.4
		10-14	35
		15-20	12

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		1798	1	0.1	.	.	21	1.2	6	0.3
	Age at baseline	<18	889	11	1.2	6	0.7
		18-19	216	1	0.5	.	.
		20-24	504	1	0.2	.	.	5	1.0	.	.
		25-29	150	2	1.4	.	.
		30-34	34	2	6.3	.	.
		35+	5
	Years since diagnosis	5-9	152	4	2.7	1	0.7
		10-14	558	6	1.1	4	0.7
		15-19	594	4	0.7	1	0.2
		20+	494	1	0.2	.	.	7	1.4	.	.
	Age at diagnosis	<1	912	1	0.1	.	.	11	1.2	4	0.4
		1-4	706	8	1.1	2	0.3
		5-9	137	1	0.7	.	.
		10-14	27	1	3.8	.	.
		15-20	16
Males	All cases		870	1	0.1	.	.	9	1.0	1	0.1
	Age at baseline	<18	440	4	0.9	1	0.2
		18-19	94
		20-24	255	1	0.4	.	.	3	1.2	.	.
		25-29	65
		30-34	14	2	14.3	.	.
		35+	2
	Years since diagnosis	5-9	72	3	4.2	1	1.4
		10-14	274
		15-19	283	2	0.7	.	.
		20+	241	1	0.4	.	.	4	1.7	.	.
	Age at diagnosis	<1	470	1	0.2	.	.	4	0.9	.	.
		1-4	317	5	1.6	1	0.3
		5-9	67
		10-14	10
		15-20	6
Females	All cases		928	12	1.3	5	0.5
	Age at baseline	<18	449	7	1.6	5	1.1
		18-19	122	1	0.8	.	.
		20-24	249	2	0.8	.	.
		25-29	85	2	2.4	.	.
		30-34	20
		35+	3
	Years since diagnosis	5-9	80	1	1.3	.	.
		10-14	284	6	2.1	4	1.4
		15-19	311	2	0.6	1	0.3
		20+	253	3	1.2	.	.
	Age at diagnosis	<1	442	7	1.6	4	0.9
		1-4	389	3	0.8	1	0.3
		5-9	70	1	1.4	.	.
		10-14	17	1	6.3	.	.
		15-20	10

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		1798	1	0.1	1	0.1	20	1.1	.	.
	Age at baseline	<18	889	.	.	1	0.1	12	1.4	.	.
		18-19	216
		20-24	504	1	0.2	.	.	3	0.6	.	.
		25-29	150	5	3.4	.	.
		30-34	34
		35+	5
	Years since diagnosis	5-9	152	.	.	1	0.7	6	4.0	.	.
		10-14	558	5	0.9	.	.
		15-19	594	1	0.2	.	.	4	0.7	.	.
		20+	494	5	1.0	.	.
	Age at diagnosis	<1	912	3	0.3	.	.
		1-4	706	1	0.1	1	0.1	13	1.9	.	.
		5-9	137	3	2.2	.	.
		10-14	27	1	3.8	.	.
		15-20	16
Males	All cases		870	1	0.1	1	0.1	10	1.2	.	.
	Age at baseline	<18	440	.	.	1	0.2	7	1.6	.	.
		18-19	94
		20-24	255	1	0.4	.	.	1	0.4	.	.
		25-29	65	2	3.1	.	.
		30-34	14
		35+	2
	Years since diagnosis	5-9	72	.	.	1	1.4	4	5.6	.	.
		10-14	274	1	0.4	.	.
		15-19	283	1	0.4	.	.	2	0.7	.	.
		20+	241	3	1.3	.	.
	Age at diagnosis	<1	470	2	0.4	.	.
		1-4	317	1	0.3	1	0.3	6	1.9	.	.
		5-9	67	2	3.0	.	.
		10-14	10
		15-20	6
Females	All cases		928	10	1.1	.	.
	Age at baseline	<18	449	5	1.1	.	.
		18-19	122
		20-24	249	2	0.8	.	.
		25-29	85	3	3.6	.	.
		30-34	20
		35+	3
	Years since diagnosis	5-9	80	2	2.5	.	.
		10-14	284	4	1.4	.	.
		15-19	311	2	0.6	.	.
		20+	253	2	0.8	.	.
	Age at diagnosis	<1	442	1	0.2	.	.
		1-4	389	7	1.8	.	.
		5-9	70	1	1.4	.	.
		10-14	17	1	6.3	.	.
		15-20	10

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		1588	5	0.3	.	.	69	4.4	7	0.4
	Age at baseline	<18	313	29	9.3	2	0.6
		18-19	115	2	1.8	.	.	5	4.4	.	.
		20-24	382	2	0.5	.	.	14	3.7	1	0.3
		25-29	351	1	0.3	.	.	14	4.0	1	0.3
		30-34	264	6	2.3	1	0.4
		35+	163	1	0.6	2	1.3
	Years since diagnosis	5-9	165	14	8.5	.	.
		10-14	473	2	0.4	.	.	31	6.6	2	0.4
		15-19	498	2	0.4	.	.	10	2.0	3	0.6
		20+	452	1	0.2	.	.	14	3.1	2	0.4
	Age at diagnosis	<1	108	3	2.8	.	.
		1-4	507	2	0.4	.	.	28	5.6	2	0.4
		5-9	361	3	0.8	.	.	25	6.9	1	0.3
		10-14	311	8	2.6	3	1.0
		15-20	301	5	1.7	1	0.3
Males	All cases		847	2	0.2	.	.	41	4.9	3	0.4
	Age at baseline	<18	179	16	8.9	1	0.6
		18-19	58	1	1.7	.	.	3	5.2	.	.
		20-24	213	7	3.3	.	.
		25-29	179	1	0.6	.	.	9	5.1	.	.
		30-34	139	5	3.6	1	0.7
		35+	79	1	1.3	1	1.3
	Years since diagnosis	5-9	89	9	10.1	.	.
		10-14	264	1	0.4	.	.	17	6.4	1	0.4
		15-19	252	5	2.0	1	0.4
		20+	242	1	0.4	.	.	10	4.2	1	0.4
	Age at diagnosis	<1	44	2	4.5	.	.
		1-4	293	1	0.3	.	.	15	5.1	1	0.3
		5-9	202	1	0.5	.	.	13	6.5	.	.
		10-14	167	7	4.2	1	0.6
		15-20	141	4	2.8	1	0.7
Females	All cases		741	3	0.4	.	.	28	3.8	4	0.5
	Age at baseline	<18	134	13	9.8	1	0.8
		18-19	57	1	1.8	.	.	2	3.6	.	.
		20-24	169	2	1.2	.	.	7	4.2	1	0.6
		25-29	172	5	2.9	1	0.6
		30-34	125	1	0.8	.	.
		35+	84	1	1.2
	Years since diagnosis	5-9	76	5	6.7	.	.
		10-14	209	1	0.5	.	.	14	6.8	1	0.5
		15-19	246	2	0.8	.	.	5	2.0	2	0.8
		20+	210	4	1.9	1	0.5
	Age at diagnosis	<1	64	1	1.6	.	.
		1-4	214	1	0.5	.	.	13	6.2	1	0.5
		5-9	159	2	1.3	.	.	12	7.5	1	0.6
		10-14	144	1	0.7	2	1.4
		15-20	160	1	0.6	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		1588	1	0.1	4	0.3	134	8.5	.	.
	Age at baseline	<18	313	.	.	1	0.3	30	9.6	.	.
		18-19	115	9	7.9	.	.
		20-24	382	1	0.3	1	0.3	26	6.8	.	.
		25-29	351	.	.	2	0.6	32	9.2	.	.
		30-34	264	21	8.0	.	.
		35+	163	16	10.0	.	.
	Years since diagnosis	5-9	165	.	.	1	0.6	21	12.9	.	.
		10-14	473	1	0.2	2	0.4	47	10.0	.	.
		15-19	498	.	.	1	0.2	30	6.1	.	.
		20+	452	36	8.1	.	.
	Age at diagnosis	<1	108	3	2.8	.	.
		1-4	507	.	.	1	0.2	36	7.2	.	.
		5-9	361	.	.	1	0.3	35	9.7	.	.
		10-14	311	1	0.3	2	0.7	29	9.4	.	.
		15-20	301	31	10.4	.	.
Males	All cases		847	1	0.1	2	0.2	75	8.9	.	.
	Age at baseline	<18	179	.	.	1	0.6	18	10.1	.	.
		18-19	58	6	10.3	.	.
		20-24	213	1	0.5	.	.	10	4.7	.	.
		25-29	179	.	.	1	0.6	21	11.9	.	.
		30-34	139	12	8.7	.	.
		35+	79	8	10.3	.	.
	Years since diagnosis	5-9	89	11	12.5	.	.
		10-14	264	1	0.4	2	0.8	29	11.0	.	.
		15-19	252	14	5.6	.	.
		20+	242	21	8.8	.	.
	Age at diagnosis	<1	44
		1-4	293	.	.	1	0.3	23	7.9	.	.
		5-9	202	17	8.5	.	.
		10-14	167	1	0.6	1	0.6	21	12.7	.	.
		15-20	141	14	10.1	.	.
Females	All cases		741	.	.	2	0.3	59	8.0	.	.
	Age at baseline	<18	134	12	9.1	.	.
		18-19	57	3	5.4	.	.
		20-24	169	.	.	1	0.6	16	9.5	.	.
		25-29	172	.	.	1	0.6	11	6.5	.	.
		30-34	125	9	7.2	.	.
		35+	84	8	9.8	.	.
	Years since diagnosis	5-9	76	.	.	1	1.3	10	13.3	.	.
		10-14	209	18	8.7	.	.
		15-19	246	.	.	1	0.4	16	6.5	.	.
		20+	210	15	7.3	.	.
	Age at diagnosis	<1	64	3	4.8	.	.
		1-4	214	13	6.2	.	.
		5-9	159	.	.	1	0.6	18	11.3	.	.
		10-14	144	.	.	1	0.7	8	5.6	.	.
		15-20	160	17	10.8	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		1931	2	0.1	.	.	18	0.9	12	0.6
	Age at baseline	<18	85	2	2.4	1	1.2
		18-19	66	3	4.5	.	.
		20-24	359	7	2.0	2	0.6
		25-29	528	2	0.4	3	0.6
		30-34	517	2	0.4	.	.	2	0.4	5	1.0
		35+	376	2	0.5	1	0.3
	Years since diagnosis	5-9	214	6	2.8	.	.
		10-14	629	4	0.6	4	0.6
		15-19	633	2	0.3	.	.	4	0.6	7	1.1
		20+	455	4	0.9	1	0.2
	Age at diagnosis	<1	8
		1-4	80	2	2.5	1	1.3
		5-9	338	6	1.8	2	0.6
		10-14	774	6	0.8	3	0.4
		15-20	731	2	0.3	.	.	4	0.6	6	0.8
Males	All cases		978	1	0.1	.	.	7	0.7	6	0.6
	Age at baseline	<18	43	1	2.3	.	.
		18-19	33	2	6.1	.	.
		20-24	174	2	1.2	.	.
		25-29	274	1	0.4	1	0.4
		30-34	255	1	0.4	4	1.6
		35+	199	1	0.5	1	0.5
	Years since diagnosis	5-9	114	4	3.5	.	.
		10-14	318	1	0.3	3	0.9
		15-19	320	1	0.3	.	.	1	0.3	2	0.6
		20+	226	1	0.4	1	0.4
	Age at diagnosis	<1	4
		1-4	41
		5-9	173	2	1.2	.	.
		10-14	362	3	0.8	1	0.3
		15-20	398	1	0.3	.	.	2	0.5	5	1.3
Females	All cases		953	1	0.1	.	.	11	1.2	6	0.6
	Age at baseline	<18	42	1	2.4	1	2.4
		18-19	33	1	3.0	.	.
		20-24	185	5	2.7	2	1.1
		25-29	254	1	0.4	2	0.8
		30-34	262	1	0.4	.	.	2	0.8	1	0.4
		35+	177	1	0.6	.	.
	Years since diagnosis	5-9	100	2	2.0	.	.
		10-14	311	3	1.0	1	0.3
		15-19	313	1	0.3	.	.	3	1.0	5	1.6
		20+	229	3	1.3	.	.
	Age at diagnosis	<1	4
		1-4	39	2	5.1	1	2.6
		5-9	165	4	2.4	2	1.2
		10-14	412	3	0.7	2	0.5
		15-20	333	1	0.3	.	.	2	0.6	1	0.3

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		1931	1	0.1	.	.	970	50.6	1	0.1
	Age at baseline	<18	85	26	30.6	.	.
		18-19	66	29	43.9	.	.
		20-24	359	181	50.6	.	.
		25-29	528	263	50.4	1	0.2
		30-34	517	1	0.2	.	.	281	54.6	.	.
		35+	376	190	51.1	.	.
	Years since diagnosis	5-9	214	115	54.0	.	.
		10-14	629	310	49.7	.	.
		15-19	633	1	0.2	.	.	334	53.0	1	0.2
		20+	455	211	46.8	.	.
	Age at diagnosis	<1	8
		1-4	80	23	28.8	.	.
		5-9	338	132	39.2	1	0.3
		10-14	774	1	0.1	.	.	432	56.2	.	.
		15-20	731	383	52.9	.	.
Males	All cases		978	501	51.6	1	0.1
	Age at baseline	<18	43	17	39.5	.	.
		18-19	33	14	42.4	.	.
		20-24	174	81	46.8	.	.
		25-29	274	137	50.7	1	0.4
		30-34	255	142	55.9	.	.
		35+	199	110	55.6	.	.
	Years since diagnosis	5-9	114	59	52.2	.	.
		10-14	318	161	51.1	.	.
		15-19	320	170	53.3	1	0.3
		20+	226	111	49.6	.	.
	Age at diagnosis	<1	4
		1-4	41	12	29.3	.	.
		5-9	173	68	39.5	1	0.6
		10-14	362	199	55.4	.	.
		15-20	398	222	56.2	.	.
Females	All cases		953	1	0.1	.	.	469	49.5	.	.
	Age at baseline	<18	42	9	21.4	.	.
		18-19	33	15	45.5	.	.
		20-24	185	100	54.1	.	.
		25-29	254	126	50.0	.	.
		30-34	262	1	0.4	.	.	139	53.3	.	.
		35+	177	80	46.0	.	.
	Years since diagnosis	5-9	100	56	56.0	.	.
		10-14	311	149	48.2	.	.
		15-19	313	1	0.3	.	.	164	52.7	.	.
		20+	229	100	44.1	.	.
	Age at diagnosis	<1	4
		1-4	39	11	28.2	.	.
		5-9	165	64	38.8	.	.
		10-14	412	1	0.2	.	.	233	56.8	.	.
		15-20	333	161	48.9	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		685	15	2.2	10	1.5
	Age at baseline	<18	54	2	3.7	1	1.9
		18-19	33	3	9.1	.	.
		20-24	157	5	3.2	2	1.3
		25-29	193	2	1.0	3	1.6
		30-34	153	1	0.7	4	2.6
		35+	95	2	2.1	.	.
	Years since diagnosis	5-9	90	5	5.6	.	.
		10-14	231	3	1.3	4	1.7
		15-19	214	3	1.4	6	2.8
		20+	150	4	2.7	.	.
	Age at diagnosis	<1	4
		1-4	50	2	4.0	1	2.0
		5-9	170	6	3.5	2	1.2
		10-14	257	4	1.6	3	1.2
		15-20	204	3	1.5	4	2.0
Males	All cases		353	6	1.7	4	1.1
	Age at baseline	<18	24	1	4.2	.	.
		18-19	17	2	11.8	.	.
		20-24	78	1	1.3	.	.
		25-29	99	1	1.0	1	1.0
		30-34	83	3	3.6
		35+	52	1	1.9	.	.
	Years since diagnosis	5-9	48	4	8.5	.	.
		10-14	109	3	2.8
		15-19	115	1	0.9	1	0.9
		20+	81	1	1.2	.	.
	Age at diagnosis	<1	2
		1-4	26
		5-9	84	2	2.4	.	.
		10-14	135	2	1.5	1	0.7
		15-20	106	2	1.9	3	2.8
Females	All cases		332	9	2.7	6	1.8
	Age at baseline	<18	30	1	3.3	1	3.3
		18-19	16	1	6.3	.	.
		20-24	79	4	5.1	2	2.5
		25-29	94	1	1.1	2	2.1
		30-34	70	1	1.4	1	1.4
		35+	43	1	2.3	.	.
	Years since diagnosis	5-9	42	1	2.4	.	.
		10-14	122	3	2.5	1	0.8
		15-19	99	2	2.0	5	5.1
		20+	69	3	4.3	.	.
	Age at diagnosis	<1	2
		1-4	24	2	8.3	1	4.2
		5-9	86	4	4.7	2	2.3
		10-14	122	2	1.6	2	1.6
		15-20	98	1	1.0	1	1.0

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
		All cases	N	%	N	%	N	%	N	%
Both sexes	All cases	685	73	10.7	1	0.1
	Age at baseline	<18	54	.	.	.	5	9.3	.	.
		18-19	33	.	.	.	6	18.2	.	.
		20-24	157	.	.	.	19	12.2	.	.
		25-29	193	.	.	.	13	6.7	1	0.5
		30-34	153	.	.	.	14	9.2	.	.
		35+	95	.	.	.	16	16.8	.	.
	Years since diagnosis	5-9	90	.	.	.	13	14.6	.	.
		10-14	231	.	.	.	29	12.6	.	.
		15-19	214	.	.	.	13	6.1	1	0.5
		20+	150	.	.	.	18	12.0	.	.
	Age at diagnosis	<1	4
		1-4	50	.	.	.	4	8.0	.	.
		5-9	170	.	.	.	10	5.9	1	0.6
		10-14	257	.	.	.	29	11.3	.	.
		15-20	204	.	.	.	30	14.8	.	.
Males	All cases	353	38	10.8	1	0.3
	Age at baseline	<18	24	.	.	.	2	8.3	.	.
		18-19	17	.	.	.	3	17.6	.	.
		20-24	78	.	.	.	10	13.0	.	.
		25-29	99	.	.	.	5	5.1	1	1.0
		30-34	83	.	.	.	11	13.3	.	.
		35+	52	.	.	.	7	13.5	.	.
	Years since diagnosis	5-9	48	.	.	.	7	14.9	.	.
		10-14	109	.	.	.	13	11.9	.	.
		15-19	115	.	.	.	7	6.1	1	0.9
		20+	81	.	.	.	11	13.6	.	.
	Age at diagnosis	<1	2
		1-4	26	.	.	.	2	7.7	.	.
		5-9	84	.	.	.	6	7.1	1	1.2
		10-14	135	.	.	.	15	11.2	.	.
		15-20	106	.	.	.	15	14.2	.	.
Females	All cases	332	35	10.6	.	.
	Age at baseline	<18	30	.	.	.	3	10.0	.	.
		18-19	16	.	.	.	3	18.8	.	.
		20-24	79	.	.	.	9	11.4	.	.
		25-29	94	.	.	.	8	8.5	.	.
		30-34	70	.	.	.	3	4.3	.	.
		35+	43	.	.	.	9	20.9	.	.
	Years since diagnosis	5-9	42	.	.	.	6	14.3	.	.
		10-14	122	.	.	.	16	13.1	.	.
		15-19	99	.	.	.	6	6.1	.	.
		20+	69	.	.	.	7	10.1	.	.
	Age at diagnosis	<1	2
		1-4	24	.	.	.	2	8.3	.	.
		5-9	86	.	.	.	4	4.7	.	.
		10-14	122	.	.	.	14	11.5	.	.
		15-20	98	.	.	.	15	15.5	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		1149	1	0.1	.	.	2	0.2	2	0.2
	Age at baseline	<18	25
		18-19	27
		20-24	183	1	0.5	.	.
		25-29	317
		30-34	337	1	0.3	.	.	1	0.3	1	0.3
		35+	260	1	0.4
	Years since diagnosis	5-9	118
		10-14	361	1	0.3	.	.
		15-19	390	1	0.3	.	.	1	0.3	1	0.3
		20+	280	1	0.4
	Age at diagnosis	1-4	21
		5-9	151
		10-14	491	2	0.4	.	.
		15-20	486	1	0.2	2	0.4
Males	All cases		577	1	0.2	2	0.3
	Age at baseline	<18	18
		18-19	12
		20-24	86	1	1.2	.	.
		25-29	165
		30-34	158	1	0.6
		35+	138	1	0.7
	Years since diagnosis	5-9	64
		10-14	190	1	0.5	.	.
		15-19	190	1	0.5
		20+	133	1	0.8
	Age at diagnosis	1-4	11
		5-9	76
		10-14	220	1	0.5	.	.
		15-20	270	2	0.7
Females	All cases		572	1	0.2	.	.	1	0.2	.	.
	Age at baseline	<18	7
		18-19	15
		20-24	97
		25-29	152
		30-34	179	1	0.6	.	.	1	0.6	.	.
		35+	122
	Years since diagnosis	5-9	54
		10-14	171
		15-19	200	1	0.5	.	.	1	0.5	.	.
		20+	147
	Age at diagnosis	1-4	10
		5-9	75
		10-14	271	1	0.4	.	.
		15-20	216	1	0.5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	All cases		1149	1	0.1	.	.	895	78.6	.	.
	Age at baseline	<18	25	21	84.0	.	.
		18-19	27	23	85.2	.	.
		20-24	183	160	87.4	.	.
		25-29	317	250	80.4	.	.
		30-34	337	1	0.3	.	.	267	79.5	.	.
		35+	260	174	68.0	.	.
	Years since diagnosis	5-9	118	101	85.6	.	.
		10-14	361	280	78.7	.	.
		15-19	390	1	0.3	.	.	321	82.7	.	.
		20+	280	193	69.9	.	.
	Age at diagnosis	1-4	21	19	90.5	.	.
		5-9	151	122	81.3	.	.
		10-14	491	1	0.2	.	.	402	82.5	.	.
		15-20	486	352	73.3	.	.
Males	All cases		577	463	81.1	.	.
	Age at baseline	<18	18	15	83.3	.	.
		18-19	12	11	91.7	.	.
		20-24	86	71	82.6	.	.
		25-29	165	132	82.0	.	.
		30-34	158	131	83.4	.	.
		35+	138	103	75.2	.	.
	Years since diagnosis	5-9	64	52	81.3	.	.
		10-14	190	148	79.1	.	.
		15-19	190	163	86.2	.	.
		20+	133	100	76.3	.	.
	Age at diagnosis	1-4	11	10	90.9	.	.
		5-9	76	62	82.7	.	.
		10-14	220	184	84.4	.	.
		15-20	270	207	77.5	.	.
Females	All cases		572	1	0.2	.	.	432	76.2	.	.
	Age at baseline	<18	7	6	85.7	.	.
		18-19	15	12	80.0	.	.
		20-24	97	89	91.8	.	.
		25-29	152	118	78.7	.	.
		30-34	179	1	0.6	.	.	136	76.0	.	.
		35+	122	71	59.7	.	.
	Years since diagnosis	5-9	54	49	90.7	.	.
		10-14	171	132	78.1	.	.
		15-19	200	1	0.5	.	.	158	79.4	.	.
		20+	147	93	64.1	.	.
	Age at diagnosis	1-4	10	9	90.0	.	.
		5-9	75	60	80.0	.	.
		10-14	271	1	0.4	.	.	218	81.0	.	.
		15-20	216	145	68.1	.	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included